MacroGenics

MGNX

Market cap $107M

Overview Fund Trends Analyst Outlook Journalist POV

1.69 USD

--0.16

8.65%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

1.70

+0.01

0.59%

1 day

-8.65%

5 days

-11.98%

1 month

-3.43%

3 months

6.96%

6 months

5.62%

Year to date

-48.79%

1 year

-49.4%

5 years

-91.49%

10 years

-94.6%

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341

Healthcare Biotechnology